{"id":3175,"date":"2021-11-10T09:53:54","date_gmt":"2021-11-10T08:53:54","guid":{"rendered":"https:\/\/cendoc.h12o.es\/blog\/?p=3175"},"modified":"2021-11-10T09:53:54","modified_gmt":"2021-11-10T08:53:54","slug":"leucemia-linfocitica-cronica-lcc-y-covid-19","status":"publish","type":"post","link":"https:\/\/cendoc.h12o.es\/blog\/2021\/11\/10\/leucemia-linfocitica-cronica-lcc-y-covid-19\/","title":{"rendered":"Leucemia linfoc\u00edtica cr\u00f3nica (LCC) y COVID-19"},"content":{"rendered":"<p>F\u00e1tima Miras, del Servicio de Hematolog\u00eda del Hospital 12 de Octubre, participa como autora en el siguiente art\u00edculo publicado en la revista <em>Leukemia<img loading=\"lazy\" decoding=\"async\" class=\" wp-image-3871 alignright\" src=\"https:\/\/coronavirusbiblioh12o.files.wordpress.com\/2020\/05\/logo12.jpg?w=233&amp;h=156\" srcset=\"https:\/\/coronavirusbiblioh12o.files.wordpress.com\/2020\/05\/logo12.jpg?w=233&amp;h=156&amp;zoom=2 1.5x\" alt=\"logo12\" width=\"233\" height=\"156\" data-attachment-id=\"3871\" data-permalink=\"https:\/\/coronavirusbiblioh12o.wordpress.com\/2020\/05\/06\/7-mas-del-h12o\/logo12\/\" data-orig-file=\"https:\/\/coronavirusbiblioh12o.files.wordpress.com\/2020\/05\/logo12.jpg\" data-orig-size=\"275,183\" data-comments-opened=\"1\" data-image-meta=\"{&quot;aperture&quot;:&quot;0&quot;,&quot;credit&quot;:&quot;&quot;,&quot;camera&quot;:&quot;&quot;,&quot;caption&quot;:&quot;&quot;,&quot;created_timestamp&quot;:&quot;0&quot;,&quot;copyright&quot;:&quot;&quot;,&quot;focal_length&quot;:&quot;0&quot;,&quot;iso&quot;:&quot;0&quot;,&quot;shutter_speed&quot;:&quot;0&quot;,&quot;title&quot;:&quot;&quot;,&quot;orientation&quot;:&quot;0&quot;}\" data-image-title=\"logo12\" data-image-description=\"\" data-image-caption=\"\" data-medium-file=\"https:\/\/coronavirusbiblioh12o.files.wordpress.com\/2020\/05\/logo12.jpg?w=275\" data-large-file=\"https:\/\/coronavirusbiblioh12o.files.wordpress.com\/2020\/05\/logo12.jpg?w=275\" \/><\/em>: \u201c<a href=\"https:\/\/www.nature.com\/articles\/s41375-021-01450-8\" target=\"_blank\" rel=\"noopener\">COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study<\/a>\u201d.<\/p>\n<p>Los pacientes con leucemia linfoc\u00edtica cr\u00f3nica (LLC) pueden ser m\u00e1s vulnerables a la COVID-19 por su enfermedad y por la inmunosupresi\u00f3n relacionada con su tratamiento. El objetivo de este estudio es evaluar los factores de riesgo y el impacto de los tratamientos. Se trata de un estudio multic\u00e9ntrico internacional llevado a cabo en 91 centros entre marzo de 2020 y marzo de 2021, y en \u00e9l se analizaron la tasa de letalidad, la gravedad y la supervivencia. La tasa de letalidad en pacientes con COVID-19 grave fue del 38%. La supervivencia fue inferior para todas las categor\u00edas de pacientes en comparaci\u00f3n con los no tratados. Los pacientes no tratados tuvieron un menor riesgo de fallecer. El riesgo de muerte fue mayor para los pacientes de m\u00e1s edad y para los que padec\u00edan insuficiencia card\u00edaca.<\/p>\n<p><em>Equipo Biblioteca H12O<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>F\u00e1tima Miras, del Servicio de Hematolog\u00eda del Hospital 12 de Octubre, participa como autora en el siguiente art\u00edculo publicado en la revista Leukemia: \u201cCOVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study\u201d. Los pacientes con leucemia linfoc\u00edtica cr\u00f3nica (LLC) pueden ser \u2026<\/p>\n<p class=\"continue-reading-button\"> <a class=\"continue-reading-link\" href=\"https:\/\/cendoc.h12o.es\/blog\/2021\/11\/10\/leucemia-linfocitica-cronica-lcc-y-covid-19\/\">Continuar leyendo<i class=\"crycon-right-dir\"><\/i><\/a><\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","enabled":false},"version":2}},"categories":[4,64,46],"tags":[],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_shortlink":"https:\/\/wp.me\/p3G9TJ-Pd","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/cendoc.h12o.es\/blog\/wp-json\/wp\/v2\/posts\/3175"}],"collection":[{"href":"https:\/\/cendoc.h12o.es\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cendoc.h12o.es\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cendoc.h12o.es\/blog\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/cendoc.h12o.es\/blog\/wp-json\/wp\/v2\/comments?post=3175"}],"version-history":[{"count":1,"href":"https:\/\/cendoc.h12o.es\/blog\/wp-json\/wp\/v2\/posts\/3175\/revisions"}],"predecessor-version":[{"id":3176,"href":"https:\/\/cendoc.h12o.es\/blog\/wp-json\/wp\/v2\/posts\/3175\/revisions\/3176"}],"wp:attachment":[{"href":"https:\/\/cendoc.h12o.es\/blog\/wp-json\/wp\/v2\/media?parent=3175"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cendoc.h12o.es\/blog\/wp-json\/wp\/v2\/categories?post=3175"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cendoc.h12o.es\/blog\/wp-json\/wp\/v2\/tags?post=3175"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}